Article Text

Download PDFPDF

ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival
Free
  1. W Weichert1,
  2. T Knösel1,
  3. J Bellach2,
  4. M Dietel1,
  5. G Kristiansen1
  1. 1Institute of Pathology, Charité University Hospital, D-10117 Berlin, Germany
  2. 2Tumour Centre, Charité University Hospital
  1. Correspondence to:
 Dr G Kristiansen
 Institute of Pathology, Charité Hospital, Campus Mitte, Schumannstr. 20/21, D-10117 Berlin, Germany; glen.kristiansencharite.de

Abstract

Background: Activated leucocyte cell adhesion molecule (ALCAM) has been implicated in tumorigenesis and tumour progression of malignant melanoma and prostate cancer.

Aims: To clarify the expression patterns of ALCAM in colon cancer and to correlate these with clinicopathological parameters, including patient survival.

Methods: One hundred and eleven colorectal carcinomas were immunostained for ALCAM (clone MOG/07) using a standard detection system. Cytoplasmic and membranous immunoreactivity were scored semiquantitatively. Fisher’s exact test, χ2 test for trends, Kaplan–Meier analysis, and Cox’s regression were applied.

Results: In colorectal cancer, 58.6% and 30.6% of cases showed strong cytoplasmic and membranous expression of ALCAM, respectively. No significant correlation with patient age, tumour grade, stage, or nodal status was apparent. In survival analyses, membranous ALCAM expression correlated significantly (Cox’s regression, p  =  0.028; relative risk, 2.3) with shortened patient survival.

Conclusions: ALCAM is frequently upregulated in colorectal cancer and is a new independent prognostic marker, underscoring the importance of ALCAM in tumour progression in this disease.

  • ALCAM, activated leucocyte cell adhesion molecule
  • WHO, World Health Organisation
  • colon cancer
  • activated leucocyte cell adhesion molecule ALCAM
  • CD166
  • immunohistochemistry
  • prognosis
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.